AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$RMD

ResMed Inc (RMD) Q1 2027 Earnings Call Highlights: Revenue Climbs 7%, EPS Jumps 14%

ResMed Inc (RMD) reported Q1 2027 revenue growth of 7% and EPS increase of 14%, with life support device revenue declining due to safety issues. Free cash flow was $374M, down YoY. The company expects inflationary pressures and a back-half headwind from France fleet renewal. Marketing campaigns and partnerships have not yet materially impacted revenue. Management maintained full-year guidance, citing various factors.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 7:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 7:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ResMed Inc (RMD) Q1 2027 Earnings Call Highlights: Revenue Climbs 7%, EPS Jumps 14% — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RMDBullishHigh
01

Why it matters

The earnings beat and buyback provide a short‑term catalyst, but unchanged guidance and noted cost pressures temper the upside.

02

Market read

The earnings surprise and buyback may drive modest buying interest in RMD, while sector peers could be impacted by the highlighted inflationary pressures.

03

What to watch

The decline in life‑support device revenue and higher inventory levels could signal margin pressure later in the year.

Relevance 8/10Novelty 8/10Timing: today

Background

ResMed reported Q1 2027 results, highlighting revenue growth, EPS beat, a large share buyback, and forward‑looking challenges such as inflation and fleet renewal headwinds.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

Q1 2027 earnings beat with revenue up 7% and EPS up 14% plus a $936 million share buyback mentioned.

Expected impact

likely slight upward pressure as the market prices in the earnings beat and buyback.

Evidence & confidence

The company delivered better-than-expected results and disclosed a large buyback, but maintained full‑year guidance, limiting upside magnitude.

Market effects

Sector

Positive for the sleep‑technology and medical‑device sector as a leading player shows resilience despite component inflation.

Regional

U.S. market may see modest gains in health‑care stocks following the beat.

Global

Limited; the news is company‑specific with no broader macro implications.

Counterpoint

What could challenge this read

Guidance unchanged and headwinds from inflation and fleet renewals could weigh on the stock if investors focus on the downside.

Key entities

  • Company
    ResMed Inc

    Medical‑device maker for sleep and respiratory therapy.

  • Executive
    Mick Farrell

    CEO of ResMed, provided commentary on growth strategy.

Read at source← All news

StoryResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders

Also covered by

4 outlets

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com